There is considerable interest in the skin as a site of anti-cancer drug application. Nevertheless, the skin poses a formidable barrier to drug penetration, thereby limiting topical and transdermal bioavailability. However, we previously showed that a thioglycolate-based depilatory agent increases the drug permeability of mouse skin. In the present report, we investigated the skin permeability and efficacy of the anti-cancer drug adriamycin increased when administered transdermally to mice in combination with a thioglycolate-based depilatory agent. Adriamycin in combination with depilatory treatment reduced Ehrlich tumor growth in hairless mice about the weight and size of harvested tumors. In addition, our delivery method for adriamycin increased the therapeutic effectiveness of this agent by decreasing toxicity. Moreover, measurement of adriamycin autofluorescence revealed that topically applied adriamycin penetrate the dermis after depilatory agent treatment. These results indicate that the transdermal delivery of anti-cancer drugs is feasible by handy pretreatment of the skin with a thioglycolate-based depilatory agent.
Marjukka, S.T.; Bouwstra, J.A.; Urtti, A. Chemical enhancement of percutaneous absorption in relation to stratum corneum structural alterations. J. Contr. Release 1999, 59, 149–161, doi:10.1016/S0168-3659(98)00187-4.
[3]
Wester, R.; Maibach, H. Percutaneous absorption of drugs. Clin. Pharmacokinet. 1992, 23, 235–266.
[4]
Shiozuka, M.; Wagatsuma, A.; Kawamoto, T.; Sasaki, H.; Shimada, K.; Takahashi, Y.; Nonomura, Y.; Matsuda, R. Transdermal delivery of a readthrough-inducing drug: A new approach of gentamicin administration for the treatment of nonsense mutation-mediated disorders. J. Biochem. 2010, 147, 463–470, doi:10.1093/jb/mvp185.
[5]
Williams, A.C.; Barry, B.W. Drug delivery routes in skin: A novel approach. Adv. Drug Deliv. Rev. 2004, 56, 603–618, doi:10.1016/j.addr.2003.10.025.
Ta, H.T.; Dass, C.R.; Larson, I.; Choong, P.F.; Dunstan, D.E. A chitosan-dipotassium orthophosphate hydrogel for delivery of Doxorubicin in the treatment of osteosarcoma. Biomaterials 2009, 30, 3605–3613, doi:10.1016/j.biomaterials.2009.03.022.
[8]
Han, I.; Kim, M.; Kim, J. Enhanced transfollicular delivery of adriamycin with a liposome and iontophoresis. Exp. Dermatol. 2004, 13, 86–92, doi:10.1111/j.0906-6705.2004.00123.x.
[9]
Elbayoumi, T.A.; Torchilin, V.P. Tumor-specific antibody-mediated targeted delivery of Doxil reduces the manifestation of auricular reythema side effect in mice. Int. J. Pharm. 2008, 5, 272–279, doi:10.1016/j.ijpharm.2008.01.041.
[10]
Sinico, C.; Fadda, A.M. Vesicular carriers for dermal drug delivery. Expert Opin. Drug Deliv. 2009, 6, 813–825, doi:10.1517/17425240903071029.
[11]
Blam, R.H.; Carter, S.K. Adriamycin: A new anticancer drug with significant clinical activity. Ann. Intern. Med. 1974, 80, 249–259, doi:10.7326/0003-4819-80-2-249.
[12]
Klein, G.; Klein, E. Conversion of solid neoplasms into ascites tumors. Ann. N. Y. Acad. Sci. 1956, 63, 640–661, doi:10.1111/j.1749-6632.1956.tb50883.x.
[13]
Durand, R.E.; Olive, P.L. Flow cytometry studies of intracellular adriamycin in single cells in vitro. Cancer Res. 1981, 41, 3489–3494.
[14]
Lee, J.N.; Jee, S.H.; Chan, C.C.; Lo, W.; Dong, C.Y.; Lin, S.J. The effects of depilatory agents as penetration enhancers on human stratum corneum structuctures. J. Invest. Dermatol. 2008, 128, 2240–2247, doi:10.1038/jid.2008.82.
